Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6756MR)

This product GTTS-WQ6756MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6756MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3376MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ2314MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ7353MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ11083MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ14221MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ10211MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ13772MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ4619MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW